Search
-
Annual Report 2016
Media
https://www.gsk.com/media/8100/annual-report-2016.pdf
First published: 01 June 2022
-
Annual Report 2022
Media
https://www.gsk.com/media/9956/annual-report-2022.pdf
First published: 10 March 2023
-
Annual Report 2018
Media
https://www.gsk.com/media/7991/annual-report-2018.pdf
First published: 01 June 2022
-
Annual Report 2023
Media
https://www.gsk.com/media/11007/annual-report-2023.pdf
First published: 01 March 2024
-
20 F 2017
Media
https://www.gsk.com/media/8002/20-f-2017.pdf
First published: 01 June 2022
-
Annual Report (1)
Media
https://www.gsk.com/media/7998/annual-report-1.pdf
First published: 01 June 2022
-
Human Genome Sciences and GlaxoSmithKline announce positive Phase 3 study results for Benlysta™ in systemic lupus erythematosus
Media
GSK & HGS announced that Benlysta met the primary endpoint in BLISS-52, Phase 3 trials in patients with serologically active SLE.
https://www.gsk.com/en-gb/media/press-releases/human-genome-sciences-and-glaxosmithkline-announce-positive-phase-3-study-results-for-benlysta-in-systemic-lupus-erythematosus/
First published: 20 July 2009
-
GSK and Genmab receive accelerated approval for Arzerra™
Media
Today, GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced the accelerated approval of Arzerra TM (ofatumumab).
https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-receive-accelerated-approval-for-arzerra/
First published: 26 October 2009
-
GSK gains accelerated FDA approval for combination use of Mekinist® (trametinib) and Tafinlar® (dabrafenib)
Media
GSK announced today that the FDA has approved Mekinist® (trametinib) for use with Tafinlar® (dabrafenib) for the treatment melanoma
https://www.gsk.com/en-gb/media/press-releases/gsk-gains-accelerated-fda-approval-for-combination-use-of-mekinist-trametinib-and-tafinlar-dabrafenib/
First published: 09 January 2014
-
US FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine), the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults
Media
Dovato strengthens ViiV Healthcare’s industry-leading portfolio of innovative treatment approaches for people living with HIV.
https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-viiv-healthcare-s-dovato-dolutegravirlamivudine-the-first-once-daily-single-tablet-two-drug-regimen-for-treatment-naïve-hiv-1-adults/
First published: 08 April 2019